Enhancing Antiplatelet Management in Carotid Artery Stenting with Impedance Aggregometry - Multiplate® Analysis

A recent retrospective study in Clinics and Practice highlights a key challenge in carotid artery stenting (CAS): many patients on standard dual antiplatelet therapy exhibit high on-treatment platelet reactivity (HTPR) — meaning the medication isn’t adequately inhibiting platelet activity, a risk factor for post-procedural thrombotic events.

What’s especially insightful is the role of Multiplate® platelet function analysis in identifying this issue. The study found:

✔️ ~31% of patients on clopidogrel showed HTPR when assessed with Multiplate®

 ✔️ Alternative P2Y12 inhibitors (like ticagrelor and ticlopidine) consistently normalized platelet reactivity in those patients

 ✔️ No residual HTPR was seen in patients switched based on Multiplate® results

👉 This demonstrates the clinical value of real-time , whole blood platelet function testing with Multiplate® — enabling personalised antiplatelet therapy rather than a one-size-fits-all approach.

By helping clinicians detect inadequate platelet inhibition early, Multiplate® testing supports better decision-making and potentially improved outcomes in vascular interventions.

Read the article here #multiplate #plateletfunction #aggregation